Protara reports Q1 net loss $9.0M; plans Phase 2 trials for TARA-002 in NMIBC and LMs

Protara Therapeutics, Inc.

2023-Q1 EPS reported -$0.80

Cash, equivalents and restricted cash $89.5M at March 31, 2023; funding expected into 2025.
Net loss $9.0M ($0.80/sh) vs $10.8M ($0.96) in Q1 2022; R&D $5.1M, G&A $4.6M.
Positive preliminary data: TARA-002 well tolerated; tumor regression in all 3 evaluable CIS patients, including a CR in a BCG-unresponsive patient.
ADVANCED-2 Phase 1b/2 trial in up to 102 CIS patients planned for 2H23; STARBORN-1 Phase 2 in pediatric LMs cleared by FDA, start Q4 2023.
IV Choline Chloride IFALD prospective study ongoing; results expected Q3 2023, then regulatory feedback.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Protara Therapeutics, Inc. reported first quarter ended March 31, 2023 results: net income a net loss of $9.0 million, EPS $0.80 per share.

Period: first quarter ended March 31, 2023
Net income: a net loss of $9.0 million
EPS: $0.80 per share
Result: reported results

Exact text from the filing

For the first quarter of 2023, Protara reported a net loss of $9.0 million, or $0.80 per share, compared with a net loss of $10.8 million, or $0.96 per share, for the same period in 2022.

View on SEC.gov

Browse all earnings releases →

Protara Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-036112

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.